DK3518948T3 - Sammensætninger og fremgangsmåder til forstærkning af vækst, spredning og onkolytisk og immunterapeutisk virkningsgrad af onkolytiske rna-vira - Google Patents

Sammensætninger og fremgangsmåder til forstærkning af vækst, spredning og onkolytisk og immunterapeutisk virkningsgrad af onkolytiske rna-vira Download PDF

Info

Publication number
DK3518948T3
DK3518948T3 DK17857734.2T DK17857734T DK3518948T3 DK 3518948 T3 DK3518948 T3 DK 3518948T3 DK 17857734 T DK17857734 T DK 17857734T DK 3518948 T3 DK3518948 T3 DK 3518948T3
Authority
DK
Denmark
Prior art keywords
oncolytic
enhancing
spread
growth
compositions
Prior art date
Application number
DK17857734.2T
Other languages
English (en)
Inventor
Mohammed Selman
Jean-Simon Diallo
Original Assignee
Ottawa Hospital Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Hospital Res Inst filed Critical Ottawa Hospital Res Inst
Application granted granted Critical
Publication of DK3518948T3 publication Critical patent/DK3518948T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20271—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK17857734.2T 2016-10-03 2017-10-03 Sammensætninger og fremgangsmåder til forstærkning af vækst, spredning og onkolytisk og immunterapeutisk virkningsgrad af onkolytiske rna-vira DK3518948T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662403586P 2016-10-03 2016-10-03
PCT/CA2017/051176 WO2018064762A1 (en) 2016-10-03 2017-10-03 Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic rna viruses

Publications (1)

Publication Number Publication Date
DK3518948T3 true DK3518948T3 (da) 2023-07-24

Family

ID=61830768

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17857734.2T DK3518948T3 (da) 2016-10-03 2017-10-03 Sammensætninger og fremgangsmåder til forstærkning af vækst, spredning og onkolytisk og immunterapeutisk virkningsgrad af onkolytiske rna-vira

Country Status (10)

Country Link
US (1) US11517598B2 (da)
EP (1) EP3518948B1 (da)
CA (1) CA3034983A1 (da)
DK (1) DK3518948T3 (da)
ES (1) ES2950435T3 (da)
FI (1) FI3518948T3 (da)
HR (1) HRP20230698T1 (da)
PT (1) PT3518948T (da)
SI (1) SI3518948T1 (da)
WO (1) WO2018064762A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019377141A1 (en) * 2018-11-06 2021-05-20 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
WO2020102295A1 (en) * 2018-11-14 2020-05-22 The Broad Institute, Inc. Vanadium compositions and methods for treatment of cancer
WO2022232944A1 (en) * 2021-05-07 2022-11-10 Ottawa Hospital Research Institute Pharmaceutical compositions comprising vanadium salts
WO2023225268A1 (en) * 2022-05-19 2023-11-23 The University Of Chicago Vanadyl sulfate compositions and methods of use therefor for the treatment and prevention of aging-related diseases and cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1390046A4 (en) 1999-04-15 2005-04-20 Wellstat Biologics Corp TREATMENT OF NEOPLASMS WITH VIRUSES
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
ES2233600T5 (es) 2000-01-21 2009-06-22 Biovex Limited Cepas de virus del herpes.
US20020037543A1 (en) 2000-06-26 2002-03-28 Atkins Harold L. Purging of cells using viruses
BR0115235A (pt) 2000-11-09 2003-10-14 Oncolytics Biotech Inc Métodos de determinar a suscetibilidade de uma célula à infecção por reovìrus, e, uso de uma composição compreendendo um ou mais reovìrus
ATE500808T1 (de) 2001-05-11 2011-03-15 Wellstat Biologics Corp Onkolytische virustherapie
US20040115170A1 (en) 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus

Also Published As

Publication number Publication date
EP3518948A1 (en) 2019-08-07
CA3034983A1 (en) 2018-04-12
WO2018064762A1 (en) 2018-04-12
ES2950435T3 (es) 2023-10-10
SI3518948T1 (sl) 2023-09-29
PT3518948T (pt) 2023-07-17
HRP20230698T1 (hr) 2023-10-13
US11517598B2 (en) 2022-12-06
FI3518948T3 (fi) 2023-07-18
EP3518948B1 (en) 2023-04-12
EP3518948A4 (en) 2020-06-24
US20190231832A1 (en) 2019-08-01
CN110022889A (zh) 2019-07-16

Similar Documents

Publication Publication Date Title
DK3510157T3 (da) Pd-1-homing-endonucleasevarianter, sammensætninger og fremgangsmåder til anvendelse
DK3782639T3 (da) Sammensætninger og fremgangsmåder til internalisering af enzymer
DK3356390T3 (da) Fremgangsmåder og sammensætninger til virusvektorer, der undgår antistoffer
DK3676297T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK3407888T3 (da) Pyridopyrroloquinoxalinforbindelser, deres sammensætninger og anvendelser
DK3842442T3 (da) Sammensætninger og fremgangsmåder til hæmning af arginaseaktivitet
DK4104687T3 (da) Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe
DK3368541T3 (da) Sammensætninger og metoder til inhibiering af arginaseaktivitet
DK3307872T3 (da) Fremgangsmåder og sammensætninger til effektiv indgivelse af nukleinsyrer og rna-baserede antimikrober
DK3012322T3 (da) Gendeleteret stamme af porcint pseudorabiesvirus, vaccinesammensætning og fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3390430T3 (da) Human immundefektvirus-antigener, vektorer, sammensætninger og fremgangsmåder til anvendelse deraf
DK3325669T3 (da) Sammensætninger og fremgangsmåder til RNA-analyse
DK3872085T3 (da) Stam-virussekvenser og anvendelser heraf
DK3302709T3 (da) Fremgangsmåder og sammensætninger til rna-guidet behandling af hiv-infektion
DK3207130T3 (da) Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme
DK3604294T3 (da) Forbindelser og sammensætninger til modulering af egfr-mutantkinaseaktiviteter
DK3262008T3 (da) Partikelformede sammensætninger til dannelse af geopolymerer, deres anvendelse og fremgangsmåder til dannelse af geopolymere dermed
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3170842T3 (da) Immunologisk effektorcelle af målrettet cld18a2, fremstillingsfremgangsmåde og anvendelse deraf
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
DK3134130T3 (da) Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3350201T3 (da) Manipulerede fytaser og fremgangsmåder til anvendelse af samme
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed